X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercepharma.com/pharma/aacr-detailed-data-spark-glimmer-hope-mercks-keytruda-lynparza-combo-lung-cancer
https://www.biospace.com/article/astrazeneca-shows-lynparza-combo-could-address-unmet-endometrial-cancer-need/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-launches-anti-cancer-generic-drug-olaparib-in-india/articleshow/108471360.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.businesswire.com/news/home/20231207532705/en/Merck-Announces-KEYLYNK-008-Trial-Evaluating-KEYTRUDA%C2%AE-pembrolizumab-Plus-LYNPARZA%C2%AE-olaparib-for-Patients-With-Metastatic-Squamous-Non-Small-Cell-Lung-Cancer-to-Stop-for-Futility
https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/
https://www.onclive.com/view/olaparib-bolsters-lutetium-lu-177-vipivotide-tetraxetan-activity-in-mcrpc
https://www.fiercepharma.com/pharma/astrazeneca-mercks-lynparza-wins-fda-nod-prostate-cancer-subgroup-following-advisory
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration#:~:text=On%20May%2031%2C%202023%2C%20the,mCRPC)%2C%20as%20determined%20by%20an
https://www.clinicaltrialsarena.com/news/astrazeneca-positive-endometrial-cancer-therapy/
https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-lynparza-prolonged-pfs-in-endometrial-cancer.html
https://news.cision.com/astrazeneca/r/imfinzi-plus-lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-adv,c3775242
https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html
https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote
https://endpts.com/fda-raises-concerns-about-plan-to-expand-lynparza-use-ahead-of-adcomm/
https://www.fiercebiotech.com/biotech/trailing-astrazeneca-and-merck-junshi-reports-phase-3-ovarian-cancer-success-lynparza-rival
https://www.thepharmaletter.com/article/nice-s-recommendation-on-lynparza-labelled-an-amazing-moment
https://www.fiercepharma.com/pharma/astrazeneca-face-tough-fda-scrutiny-imfinzi-lynparza-ovarian-cancer-analyst
https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/
https://www.pharmatimes.com/news/astrazeneca_and_msds_lynparza_gets_green_light_1489951
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-review-expanded-use-merck-astrazenecas-cancer-drug-2023-03-02/
https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-submits-application-with-usfda-for-generic-cancer-drug/articleshow/97864876.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.biopharmadive.com/news/lynparza-eu-approval-prostate-cancer-fda-parp/639298/
https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/
https://www.fiercepharma.com/pharma/fda-needs-3-more-months-review-astrazeneca-and-mercks-lynparza-first-line-prostate-cancer
https://www.fiercepharma.com/marketing/astrazeneca-merck-tap-sports-spark-prostate-cancer-conversations-never-miss-campaign
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-olaparib-tablets-73048.pdf
https://endpts.com/astrazeneca-merck-cull-one-lynparza-indication-in-heavily-pretreated-ovarian-cancer-patients/
https://www.fiercepharma.com/pharma/astrazeneca-mercks-lynparza-rejected-nice-over-pricing-issues
https://www.pharmaceutical-technology.com/news/mhra-approval-olaparib-breast-cancer/
https://www.biospace.com/article/astrazeneca-makes-waves-in-japan-with-approvals-for-tagrisso-ultomiris-and-lynparza/
https://www.globenewswire.com/news-release/2022/08/25/2504976/15459/en/Myriad-Genetics-Receives-Expanded-Coverage-in-Japan-for-Use-of-BRACAnalysis-Diagnostic-System-as-a-Companion-Diagnostic-for-Lynparza-in-Early-Stage-Breast-Cancer.html
https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-india-receives-dcgis-nod-to-market-drug-treating-breast-cancer/93669328
https://www.thepharmaletter.com/article/lynparza-combo-accepted-by-fda-for-priority-review
https://www.fiercepharma.com/financials/amarin-suspends-german-sales-force-remains-confident-european-market-despite-suspending
https://www.benzinga.com/general/biotech/22/07/28117637/merck-astrazeneca-partnered-lynparza-fails-in-late-stage-colorectal-cancer-study
https://www.europeanpharmaceuticalreview.com/news/172552/improved-outcome-for-prostate-cancer-patients-in-phase-iii-propel-trial/
https://www.biopharmadive.com/news/merck-keytruda-lynparza-prostate-cancer-trial-results/620387/
Market Place
Share 
